MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes2015 · 231 citations
2. 2Sirtuin 6 Expression and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Incretin Treatment2014 · 201 citations
3. 3Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis2014 · 48 citations
4. 4Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211)2004 · 314 citations
5. 5The role of GLP‐1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide2011 · 53 citations